HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels

HIV Medicine

Volumn 16, Issue 3, 2015, Pages 161-167

  O'Bryan, T A ^a,b   Rini, E A ^b   Okulicz, J F ^b   Messner, O ^a   Ganesan, A ^a,c   Lalani, T ^a,d   Bavaro, M F ^e   O'Connell, R J ^f   Agan, B K ^a   Landrum, M L ^a,b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d NAVAL MEDICAL CENTER PORTSMOUTH   (United States)

^e NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^f WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Antibody; Hepatitis B; HIV; Vaccine; Viraemia

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEROLOGY; TREATMENT RESPONSE; UNITED STATES; VACCINATION; VIREMIA; VIRUS LOAD; BLOOD; CLINICAL TRIAL; COHORT ANALYSIS; COMPLICATION; EPIDEMIOLOGY; FOLLOW UP; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INCIDENCE; KAPLAN MEIER METHOD; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; SOLDIER; TIME; VIROLOGY;

ADULT; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HEPATITIS B VIRUS; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MILITARY PERSONNEL; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; RNA, VIRAL; TIME FACTORS; UNITED STATES; VACCINATION; VIRAL LOAD; VIREMIA;

EID: 84922756324     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12189     Document Type: Article

References (33)

1. Thio CL, Seaberg EC, Skolasky R Jr etal. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002; 360: 1921-1926.
2. Kellerman SE, Hanson DL, McNaghten AD, Fleming PL. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in human immunodeficiency virus-infected subjects. J Infect Dis 2003; 188: 571-577.
3. Soriano V, Puoti M, Peters M etal. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B Virus International Panel. AIDS 2008; 22: 1399-1410.
4. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, Masur H. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institute of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR 2009; 58 (RR-4): 1-207.
5. Landrum ML, Hullsiek KH, Ganesan A etal. Hepatitis B vaccine responses in a large U.S. military cohort of HIV-infected individuals: another benefit of HAART in those with preserved CD4 count. Vaccine 2009; 27: 4731-4738.
6. Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 1045-1048.
7. Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Lopes MH. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005; 23: 2902-2908.
8. Landrum ML, Hullsiek KH, Ganesan A etal. Hepatitis B vaccination and risk of hepatitis B infection in HIV-infected individuals. AIDS 2010; 24: 545-555.
9. Powis JE, Raboud J, Ostrowski M, Loutfy MR, Kovacs C, Walmsley SL. The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection? J Infect Dis 2012; 205: 1534-1538.
10. Lopes VB, Hassing RJ, de Vries-Sluijs TE etal. Long-term response rates of successsful hepatitis B vaccination in HIV-infected patients. Vaccine 2013; 31: 1040-1044.
11. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIV-infected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46: 1310-1314.
12. Cruciani M, Mengoli C, Serpelloni G etal. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009; 27: 17-22.
13. Mannucci PM, Zanetti AR, Gringeri A etal. Long-term immunogenicity of a plasma-derived hepatitis B vaccine in HIV seropositive and HIV seronegative hemophiliacs. Arch Intern Med 1989; 149: 1333-1337.
14. Rey D, Krantz V, Partisani M etal. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. Vaccine 2000; 18: 1161-1165.
15. Weintrob AC, Fieberg AM, Agan BK etal. Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART. J Acquir Immune Defic Syndr 2008; 49: 40-47.
16. Brodine SK, Starkey MJ, Shaffer RA etal. Diverse HIV-1 subtypes and clinical, laboratory, and behavioral factors in a recently infected US military cohort. AIDS 2003; 17: 2521-2527.
17. Chun HM, Roediger MP, Hullsiek KH etal. Hepatitis B virus coinfection negatively impacts HIV outcomes in HIV seroconverters. J Infect Dis 2012; 205: 185-193.
18. van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. AIDS Rev 2009; 11: 157-164.
19. Slama L, Li X, Brown T etal. Increases in duration of first active antiretroviral therapy over time (1996-2009) and associated factors in the Muticenter AIDS Cohort Study. J Acquir Immune Defic Syndr 2014; 65: 57-64.
20. Geretti AM, Brook G, Cameron C etal. British HIV Association guidelines for immunization of HIV-infected adults 2008. HIV Med 2008; 9: 795-848.
21. FitzSimons D, Hendrickx G, Vorsters A, Van Damme P. Hepatitis B vaccination: a completed schedule enough to control HBV lifelong? Milan, Italy, 17-18 November 2011. Vaccine 2013; 31: 584-590.
22. Carollo M, Palazzo R, Bianco M etal. Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level. Vaccine 2013; 31: 506-513.
23. Hudu SA, Malik YA, Niazlin MT etal. Antibody and immune memory persistence post infant hepatitis B vaccination. Patient Prefer Adherence 2013; 7: 981-986.
24. Gilca V, De Serres G, Boulianne N etal. Antibody persistence and the effect of a booster dose given 5, 10 or 15 years after vaccinating preadolescents with a recombinanat hepatitis B vaccine. Vaccine 2013; 31: 448-451.
25. Lu CY, Ni YH, Chiang BL etal. Humoral and cellular immune responses to a hepatitis B vaccine booster 15-18 years after neonatal immunization. J Infect Dis 2008; 197: 1419-1426.
26. Teoharov P, Kevorkyan A, Petrova N, Baltadzhiev I, Van Damme P. Immune memory and immune response in childen from Bulgaria 5-15 years after primary hepatitis B vaccination. Pediatr Infect Dis 2013; 32: 51-53.
27. Braeckman T, Van Herck K, Jilg W, Bauer T, Van Damme P. Two decades of hepatitis B vaccination in mentally retarded patients: effectiveness, antibody persistence and duration of immune memory. Vaccine 2012; 30: 4757-4761.
28. Behre U, Bleckmann G, Crasta PD etal. Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother 2012; 8: 813-818.
29. Leuridan E, Van Damme P. Hepatitis B and the need for a booster dose. Clin Infect Dis 2011; 53: 68-75.
30. Lao-araya M, Puthanakit T, Aurpibul L, Taecharoenkul S, Sirisanthana T, Sirisanthana V. Prevalence of protective level of hepatitis B antibody 3 years after revaccination in HIV-infected children on antiretroviral therapy. Vaccine 2011; 29: 3977-3981.
31. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine 2006; 24: 572-577.
32. World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84: 405-420.
33. Mast EE, Margolis HS, Fiore AE etal. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54 (RR-16): 1-31.